Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination (MIPS)
Mumps, Measles, Rubella
About this trial
This is an interventional prevention trial for Mumps
Eligibility Criteria
Inclusion Criteria: Aged 18-49 (inclusive) at the time of the study screening visit Has received exactly two previous doses of MMR-containing vaccine at any point up to one calendar year prior to the study screening visit Willing to receive a booster MMR vaccination as outlined in the study protocol Able and willing to comply with all other study requirements (attend all study visits and provide blood, saliva, nasal wash samples at each visit as outlined) Sufficient language (German or English) and cognitive skills Provides written, informed consent to participate in the study Exclusion Criteria: Acute respiratory or other infections (postpone baseline visit until resolved) Receipt of any other vaccination less than 4 weeks prior to the baseline visit or intention to receive another vaccination within 4 weeks following the baseline visit Previous hypersensitivity reaction following receipt of any MMR-containing vaccine or previous hypersensitivity reaction to any component of M-M-R-vaxPro Pregnancy, lactation, or intention to become pregnant during the study Individuals with confirmed or suspected immunosuppressive or immune-deficient state Known current or chronic or severe disease Receipt of blood or plasma transfusions, or administration of immune globulin (IG) less than 12 weeks prior to the baseline visit, or intention to receive IG within 4 weeks following the baseline visit Any other significant disease, disorder, or finding which could potentially result in an increased risk to the volunteer due to participation in the study Being enrolled in another interventional study that may interfere with the current study
Sites / Locations
- Epidemiology, Biostatistics and Prevention Institute University of Zurich
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
MMR Booster Vaccination Arm
Observational Arm
Participants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will receive a single MMR booster vaccination (3rd lifetime dose) as M-M-R-VaxPro.
Participants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will be assessed at study enrollment and at a 1 year follow-up visit